Objective To determine the utility of dried blood spot (DBS) polymerase chain reaction (PCR) in identifying infants with cytomegalovirus (CMV) infection-associated sensorineural hearing loss (SNHL).
Conclusions DBS PCR for CMV has low sensitivity and specificity for identifying infants with CMV-associated hearing loss. These findings, together with previous reports, demonstrate that DBS PCR does not identify either the majority of CMV-infected newborns or those with CMV-associated SNHL early in life. C ytomegalovirus (CMV) is an important cause of congenital infection, and congenital CMV infection (cCMV) is a significant nongenetic cause of sensorineural hearing loss (SNHL) in children. [1] [2] [3] [4] Most congenitally infected infants (~90%) do not have obvious clinical abnormalities at birth (asymptomatic cCMV), and thus are not identified in the newborn nursery 5, 6 ; however, approximately 15% of children with asymptomatic cCMV develop SNHL. 1, 7, 8 Although CMV-associated SNHL may be present at birth, a substantial proportion of children with cCMV develop late-onset and/or progressive SNHL. 1, 9 Therefore, most children with cCMV and a significant number of those with CMV-associated SNHL are not identified on routine physical examination or hearing screening in the newborn nursery.
The need to develop rapid and reliable methods to screen newborns for CMV so that infants at increased risk for hearing loss can be identified for targeted monitoring and early intervention has been recognized. [10] [11] [12] Because dried blood spots (DBSs) are collected routinely from all infants in the US for newborn metabolic screening, and several initial studies have shown promise, the hope was that DBS polymerase chain reaction (PCR) would facilitate the development of effective strategies to screen all newborns for CMV. [13] [14] [15] [16] [17] [18] However, in a CMV screening study of 20 446 newborns, we demonstrated that the sensitivity of DBS PCR in identifying infants with cCMV was unacceptably low compared with saliva rapid culture, 19 and thus would not be a suitable screening method. Although DBS PCR failed to identify the majority of infants with cCMV, the possibility that it could detect infants at increased risk for CMV-associated SNHL remained. The present study aimed to determine the ability of the DBS PCR assay to identify infants with cCMV at risk for disease and sequelae. 19, 20 Newborn CMV screening was performed by testing saliva specimens (rapid culture or PCR) and DBS PCR as described previously. 19, 20 Between March 2007 and May 2008, all DBS specimens collected from screened infants were tested by PCR. 19 After May 2008, only DBS specimens from infants who were positive for CMV by rapid culture or PCR of saliva were tested. Demographic information, newborn hearing screening results, and saliva and DBS specimens were collected from the screening cohort. Race and ethnicity were selfreported by the parents of the infants and categorized by the National Institutes of Health's definitions for race and ethnicity. 21 DBSs for this study were collected on a separate card after obtaining the sample for routine newborn metabolic screening without an additional heel stick. The parents /guardians of the screened infants were provided the CMV screening results.
CHIMES Congenital Cytomegalovirus and
Infants were considered to have symptomatic cCMV if they had any of the following findings in the newborn period: generalized petechial rash, purpuric rash, hepatomegaly, splenomegaly, jaundice with direct bilirubin ≥3 mg/dL, unexplained neurologic/central nervous system abnormalities (eg, microcephaly, seizures, focal or generalized neurologic deficits), or chorioretinitis. Clinical decisions about evaluation and antiviral treatment of the infants infected with CMV were made by the physicians at each study site and were not part of the CHIMES study. Seventeen infants were treated with antiviral therapy, including 9 with SNHL at birth and none with lateonset SNHL. The 17 treated infants are included in the cohort for evaluating both DBS positivity and symptomatic status and DBS positivity and SNHL at birth; however, because antiviral therapy has been shown to affect hearing outcome, 22 the 17 treated infants were not included in the comparison of DBS positivity and hearing loss at age 4 years.
Medical records were reviewed for family history of hearing loss or other potential etiologies including congenital malformations that could cause SNHL. In addition, the parents were asked at enrollment about any family history of hearing loss. In addition, any new diagnosis possibly related to SNHL was collected from the parents at the follow-up visits. None of the children with SNHL had syndromes or other malformations associated with either SNHL or a family history of SNHL. Local Institutional Review Board approval was obtained at each site.
Follow-Up of Children with cCMV Infection
Infants with a positive saliva or DBS screening test were enrolled in the follow-up component of the study to confirm cCMV and to monitor hearing function during the first 4 years of life in accordance with study protocol. Infants were considered to have confirmed cCMV if the follow-up urine or saliva sample was positive by rapid culture and/or PCR. After the initial diagnostic audiologic evaluation between age 3 and 8 weeks, the study children were monitored for hearing loss using age and developmentally appropriate audiologic testing protocols every 6 months during the first 4 years of life.
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Statistical Analyses
All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, North Carolina). The 2-tailed Fisher exact test was used to assess the association between DBS positivity and symptomatic infection and hearing outcomes. Viral load levels were compared between the infants with symptomatic infection and asymptomatic infection, and those with and without hearing loss at age 4 years using the Wilcoxon ranksum test. Sensitivity, specificity, and predictive values for DBS positivity were calculated using standard methods for proportions and exact 95% CIs. Likelihood ratios (LRs) were calculated to summarize the diagnostic accuracy of the DBS PCR. The positive LR was sensitivity/(1-specificity), and the negative LR was (1-sensitivity)/specificity. The 95% CIs for LRs were determined using the method described by Simel et al. 23 
Results
During the study period., a total of 100 332 infants were enrolled and screened for cCMV. Screening DBS samples were available for 313 of 391 infants (80.1%) with confirmed cCMV, and these infants constituted the study population (Figure 1 ; available at www.jpeds.com). Reasons for unavailability of DBS specimens included collection of DBS for the routine metabolic screening before study consent was obtained (n = 72), insufficient blood for an additional study filter card (n = 2), loss of DBS sample (n = 3), and refusal by mother (n = 1). There was no difference in the proportion of infants with symptomatic cCMV and SNHL between those without a screening DBS sample and those with an available DBS. Among the 313 study children, congenital infection was confirmed by rapid culture of saliva or urine samples in 302 infants and by PCR of saliva or urine in the remaining 11 infants.
Of the 313 study children, approximately one-half were female (48.6%; 95% CI, 42.9%-54.3%) and of black race (47.0%; 95% CI, 41.3%-52.7%). The racial makeup of the remaining population was 23.0% (95% CI, 18.5%-28.1%) nonHispanic white, 25.6% (95% CI, 20.8%-30.8%) Hispanic white, 3.2% (95% CI, 1.5%-5.8%) multiracial, and 1.2% (95% CI, 0.35%-3.2%) Asian. Most infants (93.0%; 95% CI, 89.6%-95.5%) were from the well-baby nurseries and had public insurance or no insurance (80.8%; 95% CI, 76.0%-85.0%). The mean age at DBS sample collection was 2.29 ± 2.19 days.
Among the 313 infected infants, 90 DBS samples (28.8%; 95% CI, 23.8%-34.1%) were positive for CMV. DBS PCR was positive in 9 of 28 (32.1%) symptomatic infants, compared with 81 of 285 (25.9%) infants with asymptomatic cCMV at birth (P = .70) (Figure 1) . To determine whether DBS PCR has a role in identifying infants with CMV-associated SNHL at birth, we compared the results of DBS PCR between infants with hearing loss at birth and those with normal hearing (Table I) . DBS was positive in 12 of 26 (46%) infants with SNHL at birth, compared with 78 of 287 (27%) infants with normal hearing at THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 184 birth (P = .07). Among the 285 infants with asymptomatic cCMV, DBS PCR was positive in 6 of 15 (40%) with SNHL at birth, compared with 75 of 270 (28.0%) with normal hearing (P = .38). For infants with symptomatic cCMV (n = 28), DBS PCR was positive in 6 of 11 (55%) infants with hearing loss at birth, compared with 3 of 17 (18%) infants with normal hearing (P = .10). The sensitivity and specificity of PCR of newborn DBS for detecting infants with SNHL at birth were 46.2% (95% CI, 26.6%-66.6%) and 72.8% (95% CI, 67.3%-77.9%), respectively ( Table II) . The positive LR for DBS positivity was 1.7 (95% CI, 1.1-2.7), and the negative LR was 0.74 (95% CI, 0.5-1.1). The positive predictive value of the DBS PCR for detecting SNHL at birth was 13.3% (95% CI, 7.1%-22.1%) and the negative predictive value was 93.7% (95% CI, 89.7%-96.5%).
DBS at birth was positive in 11 of 26 (42%) children with SNHL at age 4 years, compared with 72 of 270 (27%) children with normal hearing (P = .11) ( Table I) . Among children with asymptomatic infection (n = 277), DBS obtained at birth was positive for CMV in 9 of 20 (45%) children who developed SNHL by age 4 years, compared with 70 of 257 (27%) with normal hearing (P = .12). Among those with symptomatic infection, DBS PCR was positive for CMV in 2 of 6 (33.3%) children with SNHL at age 4 years, compared with 2 of 13 (15.4%) children with normal hearing (P = .56). The sensitivity (42.3%; 95% CI 23.4%-63.1%) and specificity (73.3%; 95% CI, 67.6%-78.5%) remained low for DBS PCR in identifying children with SNHL at age 4 years ( Table II) . The positive and negative LRs of DBS PCR positivity to detect CMV-associated SNHL at age 4 years were 1.59 (95% CI, 0.97-2.6) and 0.79 (95% CI, 0.6-1.1), respectively. The positive and negative predictive values of the DBS PCR for detecting SNHL at age 4 years were 13.3% (95% CI, 6.8%-22.5%) and 93.0% (95% CI, 88.7%-96.0%), respectively.
We also examined whether the viral load in DBS is predictive of symptomatic infection and CMV-associated SNHL. There was no difference in median DBS CMV viral load between infants with symptomatic infection (3.0 × 10 3 IU/mL; range, 3.3 × 10 2 -6.5 × 10 3 IU/mL) and those without clinical findings at birth (2.3 × 10 3 IU/mL; range, 1.7 × 10 2 -1.9 × 10 5 IU/mL; P = 1.00) (Figure 2) . DBS viral load at birth did not differ between those children with SNHL at birth (3.1 × 10 3 IU/mL; range, 8.3 × 10 2 -1.9 × 10 5 IU/mL) and those with normal hearing (2.3 × 10 3 IU/mL; range, 1.7 × 10 2 -6.9 × 10 4 IU/mL; P = .51) Similarly, the median DBS viral load was not different between the group of children who developed SNHL by age 4 years (2.0 × 10 3 IU/mL; range, 8.3 × 10 2 -7.1 × 10 4 IU/mL) and those with normal hearing (2.5 × 10 3 IU/mL; range, 1.7 × 10 2 -6.9 × 10 4 IU/mL; P = .44) (Figure 2) .
Discussion
Our findings demonstrate that PCR testing of newborn DBS for CMV DNA has low sensitivity and specificity for identifying infants with CMV-associated hearing loss at birth as well as at age 4 years of age. We previously reported that our PCR method to detect CMV in DBS specimens has low sensitivity (~32%) for identifying infants with cCMV. 19 Although cCMV is an important nongenetic cause of SNHL in children, most infected infants are not identified at birth. The identification of predictors of adverse outcome in cCMV is urgently needed, especially for infants with asymptomatic infection at increased risk for SNHL. Our findings in the present study, together with those of our previous study, demonstrate that DBS PCR is not useful in identifying most congenitally infected infants, and that DBS PCR does not identify the majority of infants at risk for CMV-associated SNHL. Among infants with asymptomatic cCMV, DBS PCR failed to identify more than one-half of the children who developed SNHL. Furthermore, a positive likelihood ratio close to 1 for both SNHL at birth and at age 4 years indicates that a positive DBS result at birth has poor diagnostic accuracy for detecting hearing loss in cCMV. The negative LRs for DBS positivity at birth are not sufficiently small to rule out the development of hearing loss in infants with a negative DBS at birth.
In an attempt to identify a marker for hearing outcome, some previous studies have examined the relationship between blood viral load and SNHL in cCMV and have reported conflicting findings. [24] [25] [26] [27] In most of those studies, PCR of whole blood was performed to assess viral load, which may be different from DBS viral load. In a retrospective study, Walter et al 27 examined the association between DBS viral load and hearing loss in 39 children with known cCMV, and found a higher DBS viral load in children with hearing loss compared with children with normal hearing (2.69 logs vs 1.64 logs). In contrast, the findings of our large prospective study that included 313 children with cCMV show no difference in median viral load between children with SNHL and those with normal hearing. Of note, in the study reported by Walter et al, DBS PCR was negative in 11 of 39 infants with cCMV, and 5 of the infants with negative DBS developed SNHL. 27 These data, along with our current findings, indicate that neither DBS positivity nor viral load level is a useful prognostic markers of hearing outcome in cCMV.
A limitation of this study is that DBS specimens were not available for all infants who tested positive for CMV on newborn screening. However, specimens from most (313 of 391; 80%) of the infants with confirmed cCMV, including those with asymptomatic infection, could be tested. In addition, there were no differences in the frequency of symptomatic infection and hearing loss in children with unavailable DBS compared with the study population. Therefore, the unavailability of DBS in approximately 20% of the infants is unlikely to have influenced our findings in this study. An additional limitation is that the study children were monitored only for hearing function, and thus the association between DBS PCR assay results and other long-term outcomes, such as cognitive and motor deficits, could not be determined. Nonetheless, the frequency of cognitive and motor deficits was significantly lower than that hearing impairment in children with cCMV, particularly in children with asymptomatic infection, which will require screening and follow-up of a much larger number of children.
Another potential limitation of this study is the sensitivity of our DBS PCR assay to detect cCMV, which is <40%. 19 In this study, the sensitivity of DBS PCR for identifying infants with CMV-associated SNHL at birth as well as at age 4 years was also low (42%). It is possible that the sensitivity of the DBS PCR assay could be improved in the future by using different DNA extraction protocols and further optimizing the PCR assay. Such an improved DBS PCR method may have a better predictive value for identifying children at increased risk for CMV-associated SNHL. However, even if different extraction protocols or other assay enhancements improve DBS PCR detection in the laboratory, it is essential that these protocols be evaluated in large screening cohorts of newborns.
In summary, the findings of this study show the poor utility of testing newborn DBS specimens for the identification of infants with CMV-associated SNHL. These findings, together with those from our previous report, demonstrate that DBS PCR does not identify the majority of CMV-infected newborns or those with CMV-associated SNHL early in life. ■ We are indebted to the infants and their parents who agreed to take part in this study. 
